What is the role of biomarkers in the prevention of HF?
Natruiretic peptide biomarkers can be used for screening patients at risk of developing HF. This can be followed by team-based care, including a cardiovascular specialist optimizing GDMT, to prevent the development of left ventricular dysfunction (systolic or diastolic). New data suggest that natriuretic peptide biomarker screening and early intervention may help to prevent HF.